| | | | | ||||||
| Overview | Overview | Overview | Calendar & Alerts | Contact | ||||||
| Board of Directors | Parkinson's Disease | Financial Statements | Privacy Statement | |||||||
| Senior Management | Corporate Policies | Legal Notice | ||||||||
| Scientific Advisors |
| | | | | ||||||
| Overview | Overview | Overview | Calendar & Alerts | Contact | ||||||
| Board of Directors | Parkinson's Disease | Financial Statements | Privacy Statement | |||||||
| Senior Management | Corporate Policies | Legal Notice | ||||||||
| Scientific Advisors |
Press Releases
|
Press ReleasesMay 15, 2013 Cynapsus Publishes White Paper on Apomorphine for ‘Off’ Periods in Parkinson's Disease and Its Alternative Delivery Development Candidate APL-130277Cynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing the only known orally administered (sublingual) formulation of apomorphine, the only drug approved to treat the immobility (“off”) symptoms of Parkinson’s disease, has completed a white paper providing background clinical information on apomorphine. May 9, 2013 Cynapsus Announces Completion of Short Form Prospectus OfferingCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, announced today that it has completed its previously announced offering (the "Offering") under the Company’s short form prospectus dated February 21, 2013, as amended by an amendment dated March 8, 2013. May 9, 2013 Cynapsus Therapeutics Appoints Two New DirectorsCynapsus Therapeutics Inc. (TSX-V: CTH), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced that Tomer Gold, the current Vice President, Research & Development of Dexcel Pharma (“Dexcel”), and Ilan Oren, currently Vice President, Business Development at Dexcel, will be joining its Board of Directors effective May 9, 2013. May 1, 2013 Cynapsus Therapeutics Grants Stock OptionsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, announced today that the Corporation's Board of Directors granted stock options to acquire 1,392,000 common shares. April 26, 2013 Cynapsus Therapeutics Reports 2012 Financial Results and Highlights Key DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced its results for the fourth quarter and fiscal year ended December 31, 2012. March 21, 2013 Cynapsus Raises Additional $1.3 Million As Part Of Short Form Prospectus OfferingCynapsus Therapeutics Inc. (CTH: TSX-V) is pleased to announce that it has completed a second closing of its short form prospectus offering (the "Offering") of units ("Units") for gross proceeds of $1,309,160 (the “Second Closing”). On March 1, 2013, the Company completed a first closing of the Offering for gross proceeds of $6,008,000 (the “First Closing”). Total gross proceeds from the First Closing and the Second Closing of the Offering are equal to $7,317,160. March 14, 2013 Cynapsus Announces Continuation Of Short Form Prospectus OfferingCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it is continuing its previously announced offering (the "Offering") under the Company’s short form prospectus dated February 21, 2013 (the “Prospectus”). March 1, 2013 Cynapsus Therapeutics Completes $6 Million Short Form Prospectus OfferingCynapsus Therapeutics Inc. (CTH: TSX-V) is pleased to announce that it has completed its previously announced short form prospectus offering (the "Offering") of units ("Units") for aggregate gross proceeds of $6,008,000. Concurrent with the closing of the Offering, the Company and the holders of Series A to E debentures agreed to convert $4,031,406 in debt for common shares and warrants. In addition, the Company completed a share consolidation of the Company’s issued and outstanding common shares concurrent on the basis of one (1) new common share for every ten (10) common shares issued and outstanding. February 22, 2013 Cynapsus Therapeutics Files Final Short Form ProspectusCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it has received a receipt for its final short form prospectus (the “Prospectus”) which was filed with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with a best efforts offering of common shares and warrants of Cynapsus for gross proceeds of $6 million to $8 million (the December 11, 2012 Cynapsus Therapeutics Receives Notice of Allowance from United States Patent and Trademark Office (USPTO)Cynapsus Therapeutics Inc. (CTH: TSX-V) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent application 13/445,656 with critical claims directed to thin film compositions containing apomorphine formulated for sublingual administration. November 26, 2012 Cynapsus Therapeutics Files Preliminary Short Form ProspectusCynapsus Therapeutics announced today that it has filed a preliminary short form prospectus (the “Prospectus”) with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with a best efforts offering of common shares and warrants of Cynapsus for gross proceeds of $6 million to $8 million (the "Offering"). November 23, 2012 Cynapsus Announces Closing of Private PlacementCynapsus Therapeutics Inc., a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced that it has closed a brokered private placement (the November 15, 2012 Cynapsus Therapeutics Reports Third Quarter 2012 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing the only non-injectable (i.e. sublingual) delivery of the only approved drug (apomorphine) for the rescue of “off” episodes in Parkinson’s disease, today announced its results for the three and nine months ended September 30, 2012. October 29, 2012 Cynapsus Therapeutics’ APL 130277 For Parkinson’s Chosen As One Of The Top Ten Neurology Projects To Watch For 2012Cynapsus Therapeutics Inc. today announced that its APL-130277 for Parkinson’s was recognized as one of the Top Ten Neurology Projects to Watch in 2012 by a joint selection committee including Dr. Harry Tracy, a noted authority on pharmacological interventions for diseases of the brain and editor of the highly respected biotechnology publication NeuroPerspective, as well as with Elsevier Business Intelligence, the publishers of In Vivo, Startup and The Pink Sheet. October 24, 2012 Cynapsus Announces Closing of Private PlacementCynapsus Therapeutics Inc. today announced that it has closed a brokered private placement of units. Cynapsus issued an aggregate of 3,400,000 Units at a price of $0.05 per Unit raising gross proceeds of $170,000. October 3, 2012 Cynapsus Therapeutics Signs Term Sheet for C$7 Million OfferingCynapsus Therapeutics Inc. (CTH: TSX-V) today announced that it has signed a term sheet with a Health Care / Life Sciences focused Institutional Investment Group (the “Lead Investor”) to be the lead investor in a short form prospectus offering of C$7 million of its common shares and warrants (the “Offering”). August 29, 2012 Cynapsus Therapeutics Reports Second Quarter 2012 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing the only oral formulation of the only approved drug (apomorphine) for the rescue of “off” episodes in Parkinson’s disease, today announced its results for the three and six months ended June 30, 2012. August 8, 2012 Cynapsus Therapeutics Awarded Grant from The Michael J. Fox FoundationCynapsus Therapeutics Inc. (CTH: TSX-V) today announced that it has been awarded a grant of USD$947,925 from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support clinical studies to develop APL-130277, a sublingual (oral) thin film strip reformulation of apomorphine. July 18, 2012 Cynapsus Announces Closing of Private PlacementCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced that it has closed a non-brokered private placement (the "Private Placement") of units ("Units"). Cynapsus issued an aggregate of 2,000,000 Units at a price of $0.05 per Unit raising gross proceeds of $100,000. June 13, 2012 Cynapsus Therapeutics Has Article Published in Journal of Commercial BiotechnologyCynapsus Therapeutics (TSX-V: CTH) today announced that an article discussing its APL-130277 drug candidate will be published in the July 2012 Issue of the Journal of Commercial Biotechnology. June 1, 2012 BlueCross BlueShield policy gives boost to CynapsusA recent on-line posting by the Pharmacy and Therapeutic Committee of BlueCross BlueShield of Mississippi indicates that Apokyn (apomorphine hydrochloride) is considered “medically necessary” for patients experiencing hypomobility, or “off” episodes, associated with advanced Parkinson’s disease as determined by a board certified neurologist. May 30, 2012 Cynapsus Therapeutics Reports First Quarter 2012 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced its results for the three months ended March 31, 2012. May 17, 2012 Cynapsus Therapeutics Retains US Investor Relations FirmCynapsus Therapeutics Inc. (TSX-V: CTH) today announced that it has retained JSDC, Inc. to provide US-based investor relations services for the Company. May 3, 2012 Cynapsus Therapeutics Nominates New Directors for BoardCynapsus Therapeutics Inc. (“Cynapsus”) (http://www.cynapsus.ca) (TSX-V: CTH) today announced that Dr. Perry Molinoff, the former Vice Provost of the University of Pennsylvania, and Dr. Thomas Picone, a seasoned senior pharma executive, will be nominated to join its Board of Directors. April 23, 2012 Cynapsus Therapeutics appoints Dr. Abraham Lieberman to Clinical Advisory BoardCynapsus Therapeutics, a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced that it has appointed Dr. Abraham Lieberman to its Clinical Advisory Board (CAB). April 16, 2012 Cynapsus Provides Update and 2012 OutlookAnthony Giovinazzo, President and CEO of Cynapsus Therapeutics (CTH: TSX-V), has provided shareholders with a strategy update in an open letter that is available on the company web site (www.cynapsus.ca). March 26, 2012 Cynapsus Therapeutics Reports 2011 Financial Results and Highlights Key DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced its results for the fourth quarter and fiscal year ended December 31, 2011. March 9, 2012 Cynapsus Therapeutics Announces $1 Million FinancingCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it has arranged a financing (the "Financing") of secured Series E5 Debentures ("Secured Debentures") in the aggregate principal amount of $1,075,865. February 29, 2012 Loewen, Ondaatje, McCutcheon Initiates Independent Analyst Coverage on Cynapsus TherapeuticsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing a rescue therapy for Parkinson’s disease, today announced that Loewen, Ondaatje, McCutcheon Limited ( February 13, 2012 Cynapsus' President and CEO interview to air on Ichannel’s The Next Biggest Winner programCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing a rescue therapy for Parkinson’s disease, today announced that an interview with Anthony Giovinazzo, President and CEO, will air on Ichannel’s The Next Biggest Winner program on Tuesday, February 14th at 7:30 pm. January 10, 2012 Cynapsus Announces Successful Human Volunteer Pilot Proof-of-Concept Results For APL-130277Cynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company, today announced positive headline data from its recently completed human volunteer pilot proof-of-concept trial for APL 130277, a sublingual thin film strip formulation of apomorphine. December 28, 2011 Cynapsus Announces Debenture FinancingCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it has arranged a financing (the "Financing") of secured Series E-4 Debentures ("Secured Debentures") in the aggregate principal amount of $229,885. December 28, 2011 Noverra Research Analysts Issue Watch List Report on Cynapsus TherapeuticsCynapsus Therapeutics advises that Noverra Research, a provider of independent equity research, has released a comprehensive report that describes Cynapsus’ business along with its recommendations. This 10-page report includes detailed information about the Parkinson’s disease market, Cynapsus’ APL-130277 project and strategy, as well as other company-related information and associated risks. December 22, 2011 Cynapsus Therapeutics Announces Completed Acquisition of Adagio PharmaceuticalsCynapsus Therapeutics Inc. (CTH: TSX-V) announced today the completion of the acquisition of Adagio Pharmaceuticals Ltd. as announced on April 26, 2011 and August 17, 2011. December 15, 2011 Cynapsus Announces Debenture FinancingCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it has arranged a second closing financing (the December 8, 2011 Neurologist Survey Confirms Need for Improved Administration of Parkinson’s Disease Acute Rescue TherapyCynapsus Therapeutics Inc. (CTH: TSX-V) announced today the results of a large survey of neurologists and movement disorder specialists in the United States, Europe, Japan, China and select countries in the Rest of the World. November 30, 2011 Cynapsus Announces Results of Special Meeting of ShareholdersCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, announced the results of its Special Meeting of Shareholders held on November 30, 2011. November 23, 2011 Cynapsus Announces Parkinson’s Drug Candidate Progress and Upcoming MilestonesAnthony Giovinazzo, President and CEO of Cynapsus Therapeutics (CTH: TSX-V), has provided shareholders with a strategy update in an open letter that is available on the company web site (www.cynapsus.ca) and below. November 10, 2011 Cynapsus Therapeutics Announces Third Quarter 2011 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced its results for the nine months ended September 30, 2011. November 8, 2011 Cynapsus Announces Debenture Financingynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it has arranged a second closing financing (the "Financing") of secured Series E Debentures ("Secured Debentures") in the aggregate principal amount of $172,414. September 29, 2011 Cynapsus Announces Debenture Financing and Upcoming MilestonesCynapsus Therapeutics Inc. (“Cynapsus” or the “Corporation”) (CTH: TSX-V) announced today that it has arranged financing (the "Financing") of secured Series E Debentures ("Secured Debentures") in the aggregate principal amount of $488,503. August 22, 2011 Cynapsus Therapeutics Announces Second Quarter 2011 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced its results for the six months ended June 30, 2011. August 17, 2011 Cynapsus Provides Update on Proposed Acquisition of Adagio Pharmaceuticals and FinancingCynapsus Therapeutics Inc. (the "Corporation" or "Cynapsus") (CTH: TSX-V) announced today that it intends to proceed with the acquisition of Adagio Pharmaceuticals Ltd. ("Adagio") as previously announced on April 26, 2011 (the “Proposed Transaction”) and conduct a Series E Debenture financing. August 15, 2011 IN VIVO: Will New Drugs For Motor Symptoms Of Parkinson's Disease Deliver?Because of the severity of the disease and the unmet medical need, competition to develop more effective treatments for motor complications of Parkinson's disease is fierce. Biopharma companies are employing a variety of strategies including reformulating approved drugs via new delivery systems and developing first-in-class therapies, which although riskier scientifically may command higher prices and greater acceptance from payors. June 24, 2011 Cynapsus Therapeutics Provides Research Update for Parkinson’s Drug CandidateCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today provided an update on the progress of its research activities on its lead drug candidate, APL-130277. June 21, 2011 Cynapsus Provides Update on Brokered Private PlacementCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today provided an update on its previously announced private placement financing (“the Offering”) of its common shares and warrants. June 17, 2011 Cynapsus Therapeutics Announces First Quarter 2011 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced its results for the three months ended March 31, 2011. The first quarter of 2011 represents the Company's first reporting period under International Financial Reporting Standards (IFRS). May 31, 2011 Cynapsus Announces Results of Annual and Special Meeting of ShareholdersCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced the results of its Annual and Special Meeting of Shareholders held earlier in the day, on May 31, 2011. May 31, 2011 Cynapsus Therapeutics to Present at BioFinance 2011 ConferenceCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, announced today that Anthony Giovinazzo, President and Chief Executive Officer, will present an overview of the Company at the BioFinance 2011 Conference, being held this week in Toronto. May 26, 2011 Cynapsus Announces Debenture FinancingCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it has arranged financing of secured Series D Debentures in the aggregate principal amount of $500,000. May 25, 2011 Cynapsus Therapeutics Signs Term Sheet for C$10 Million Private Placement OfferingCynapsus Therapeutics Inc. (CTH: TSX-V) today announced that it has signed a term sheet with a Health Care / Life Sciences focused Institutional Investment Group to be the lead investor in a private placement offering of C$10 million of its common shares and warrants. April 26, 2011 Cynapsus Announces Proposed Acquisition of Adagio Pharmaceuticals and Private PlacementCynapsus Therapeutics Inc. (the "Corporation" or "Cynapsus") (CTH: TSX-V) is pleased to announce that it has entered into a preliminary agreement dated April 26, 2011 with Adagio Pharmaceuticals Ltd. ("Adagio") providing for the acquisition by Cynapsus of all of the issued and outstanding shares of Adagio in a share exchange (the "Proposed Transaction"). April 12, 2011 BioWorld Insight: Parkinson’s Update: Disease Pipeline Running the GamutThere were roughly 40 million Americans over the age of 65 in 2010, but as the baby boomer generation continues to reach the monumental age, the number of Americans in that class is expected to increase to 70 million in 2030. April 5, 2011 The Burrill Report: An Interview With Anthony Giovinazzo, President and CEO, Cynapsus TherapeuticsCynapsus Therapeutics is a small Canadian specialty pharma trying to reinvent itself. Under Anthony Giovinazzo, who took the helm at the end of 2009, the company has a new name and new focus. March 23, 2011 BioPharm Insight: Cynapsus seeking CRO for studies of lead PD agent; plans to find global partner post completion of pivotal study - CEOCynapsus Therapeutics (CVE:CTH) is currently engaging in discussions with CROs to help run a Phase I study of lead agent APL-130277, a sublingual formulation of apomorphine, an approved agent used to treat “off-episodes” of patients with advanced Parkinson’s disease (PD), CEO Anthony Giovinazzo said. March 22, 2011 Cynapsus Announces Resignation of Chairman David Pattenden; Rochelle Stenzler Elected as New ChairpersonCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that Rochelle Stenzler, the current Chair of the Corporate Governance and Compensation Committee, was elected to the position of Chairperson. Ms. Stenzler will replace Mr. David Pattenden, who resigned as a director and Chairman for personal reasons. March 7, 2011 Cynapsus Therapeutics Announces Fourth Quarter and Full-Year 2010 Financial Results and Recent DevelopmentsCynapsus Therapeutics Inc. (CTH: TSX-V), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease, today announced its results for the year ended December 31, 2010. February 18, 2011 Cynapsus Therapeutics to Present at the BIOCOM Global Life Science Partnering ConferenceCynapsus Therapeutics Inc. (CTH: TSX-V) today announced that Anthony J. Giovinazzo, President and Chief Executive Officer, will present at the BIOCOM Global Life Science Partnering Conference at 4:45 P.M. PST, Wednesday, February 23rd, at the Estancia Hotel & Spa in La Jolla, California. February 3, 2011 Cynapsus Announces Closing of Private Placementynapsus Therapeutics Inc. is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of units ("Units") effective February 2, 2011. January 28, 2011 Cynapsus Announces Debenture FinancingCynapsus Therapeutics Inc. (“Cynapsus” or the “Corporation”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V) announced today that it has arranged financing (the "Financing") of secured Series C Debentures ("Secured Debentures") in the aggregate principal amount of $300,000. January 7, 2011 Cynapsus President and CEO Provides Update with Open LetterAnthony Giovinazzo, President and CEO of Cynapsus Therapeutics (CTH: TSX-V), has provided shareholders with a strategy update in an open letter that is available on the company web site (www.cynapsus.ca) and below. January 4, 2011 Cynapsus Announces Signing of Definitive License AgreementCynapsus Therapeutics Inc. (CTH: TSX-V) today announced that on December 31, 2010, it executed a Definitive License Agreement with IntelGenx Corp., its former development partner, whereby IntelGenx agrees to pay a royalty on future sales of the INT0010 (formerly Relivar), a buccal/sublingual formulation of THC (dronabinol) for the symptomatic management of Multiple Sclerosis induced neuropathic pain and other conditions. December 17, 2010 Cynapsus Therapeutics Announces Transfer of Common SharesCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that, effective December 16, 2010, pursuant to the terms of a security purchase agreement dated as of November 15, 2010 among Lorne Gertner and David Hill (collectively, the December 15, 2010 Cynapsus Signs Engagement Letter With Summer Street Research Partners to Provide Financial and Advisory ServicesCynapsus Therapeutics Inc. (CTH: TSX-V) is pleased to announce that it has retained Summer Street Research Partners to provide financial and advisory services. December 2, 2010 Cynapsus Announces Positive Proof of Concept Results in Animals for Parkinson’s Drug CandidateCynapsus Therapeutics Inc. (CTH: TSX-V) is providing today an update on the progress of its research activities on its lead drug candidate, APL 130277, a potential treatment for patients with Parkinson’s disease. November 29, 2010 Cynapsus Announces Signing of Memorandum of UnderstandingCynapsus Therapeutics Inc. (CTH: TSX-V) today announced it has executed a binding Memorandum of Understanding with IntelGenx Corp. November 24, 2010 Cynapsus Announces Debenture FinancingCynapsus Therapeutics Inc. (CTH: TSX-V) announced today that it has secured financing of a secured Series B debenture in the aggregate amount of $100,000. November 11, 2010 Cynapsus Therapeutics Reports Results for the Nine Months Ended September 30, 2010Cynapsus Therapeutics Inc. (CTH: TSX-V), a specialty clinical development pharmaceutical company targeting CNS diseases, today announced its results for the nine months ended September 30, 2010. November 8, 2010 Cynapsus obtains survey results forecasting favourable acceptance of APL 130277 for Parkinson’s, by US HMOs and InsurersCynapsus Therapeutics Inc. (“Cynapsus”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V) announced today that it had received favourable results from a survey conducted by a leading independent healthcare market research group. September 23, 2010 Cynapsus Provides Research Update for Parkinson’s Drug CandidateCynapsus Therapeutics Inc. (“Cynapsus”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V) is providing today an update on the progress of its research activities on its lead drug candidate, APL 130277, a potential treatment for patients with Parkinson’s disease. August 13, 2010 Cynapsus Therapeutics Reports Results for the Six Months Ended June 30, 2010Cynapsus Therapeutics Inc. (CTH: TSX-V), a specialty clinical development pharmaceutical company targeting CNS diseases, today announced its results for the six months ended June 30, 2010. August 5, 2010 Cynapsus Announces Formation of Clinical Advisory Board For Parkinson’s ProgramCynapsus announced today the formation of an international Clinical Advisory Board (“CAB”). The CAB, which is made up of world class knowledge expert physicians, beginning with Dr. Warren Olanow and Dr. Fabrizio Stocchi, will provide counsel and guidance on a range of clinical design and management issues. August 4, 2010 Cynapsus Announces Additional Debenture FinancingCynapsus Therapeutics Inc. announced today that it has completed an additional financing of secured debentures in the aggregate amount of $180,000. July 29, 2010 Cynapsus Announces Addition of Dr. Albert Agro to Parkinson’s Program TeamCynapsus Therapeutics Inc. announced today that it has entered into an agreement with Dr. Albert Agro, an international clinical development expert in CNS diseases. July 27, 2010 Cynapsus Announces Parkinson’s Disease Survey ResultsCynapsus Therapeutics announced today the results of a survey of neurologists and movement disorder specialists relating to Parkinson’s (PD) practices and treatments, specifically targeted at analyzing the use of apomorphine products. July 26, 2010 Cynapsus Announces Signing of License Option Agreement of Parkinson’s Disease TechnologyCynapsus Therapeutics Inc. announced today that it has entered into a License Option Agreement with Adagio Pharmaceuticals Ltd. July 19, 2010 Cynapsus Announces Debenture FinancingCynapsus Therapeutics Inc. announced today that it has secured financing of secured debentures in the aggregate amount of $520,000. June 2, 2010 Cynapsus Amends Terms and Conditions of Brokered Private PlacementCynapsus Therapeutics Inc. (“Cynapsus”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V) announced today that the terms and conditions for the previously announced brokered private placement have been amended due to market conditions. May 28, 2010 Cynapsus Therapeutics Reports Results for the Three Months Ended March 31, 2010Cynapsus Therapeutics Inc. (“Cynapsus”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V), a specialty clinical development pharmaceutical company targeting CNS diseases, today announced its results for the three months ended March 31, 2010. May 7, 2010 Cynapsus Confirms Terms and Conditions of Brokered Private PlacementCynapsus Therapeutics Inc. (“Cynapsus”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V) announced today that the terms and conditions for the previously announced brokered private placement will remain as initially set, with each of the units (each a “Unit”) priced at $0.10 per Unit (the “Offering”) for gross proceeds of up to CDN$2,500,000. April 15, 2010 Cannasat Changes Name to Cynapsus TherapeuticsCannasat Therapeutics Inc. (CTH:TSX-V) (“Cannasat”) today announced that it received shareholder approval to change its corporate name to Cynapsus Therapeutics Inc. (“Cynapsus”). The approval was granted at the Annual General Shareholder Meeting held yesterday in Toronto. The Company’s stock symbol will remain as “CTH” on the TSX Venture Exchange. April 7, 2010 Cannasat Therapeutics Announces Private PlacementCannasat Therapeutics Inc. (CTH: TSX-V) today announced it intends to raise gross proceeds of up to CDN$2,500,000 through a brokered private placement of units at a price of $0.10 per Unit. April 6, 2010 Cannasat Therapeutics to Present at BioFinance 2010 ConferenceCannasat Therapeutics (CTH: TSX-V) announced today that Anthony Giovinazzo, President and Chief Executive Officer, will present an overview of the Company at the BioFinance 2010 Conference, being held this week in Toronto. March 9, 2010 BioTuesday: Cannasat Batting Hot Streak in its CNS TurnaroundNewly installed in the executive suite at Cannasat Therapeutics (TSX-V:CTH) last November, Mr. Giovinazzo’s mandate is to rebrand the company, founded in 2004 by Moses Znaimer to treat pain with a cannabinoid derivative, into a specialty central nervous system (CNS) drug company. March 5, 2010 Cannasat Therapeutics Reports Results for the Year Ended December 31, 2009Cannasat Therapeutics Inc. (CTH: TSX-V), a specialty clinical development pharmaceutical company targeting CNS diseases, today announced its results for the year ended December 31, 2009. March 4, 2010 IntelGenx and Cannasat Announce Letter of Intent for Relivar LicenseIntelGenx Corp. and Cannasat Therapeutics announced today that they have entered into a Letter of Intent (“LOI”). Under the terms of the LOI, IntelGenx would acquire a fifty percent ownership stake from Cannasat and an exclusive worldwide license to develop and commercialize Relivar, a novel formulation of dronabinol. February 4, 2010 Cannasat Announces Signing of Letter of Intent for In-licensing of Parkinson’s Disease TechnologyCannasat Therapeutics, a specialty clinical development pharmaceutical company targeting CNS illness, announced today that it has entered into a Letter of Intent (“LOI”) with Adagio Pharmaceuticals Ltd. granting Cannasat the option to execute a proposed exclusive, worldwide agreement to license all intellectual property relating to APL-130277, a reformulation of an approved Parkinson’s drug. February 1, 2010 Cannasat Update From Anthony Giovinazzo, President & CEOI want to take this opportunity to give you an update on our progress at Cannasat Therapeutics since my appointment as President and CEO on November 16th, 2009. January 11, 2010 Cannasat Therapeutics Strengthens its Board of DirectorsCannasat Therapeutics Inc., a specialty clinical development pharmaceutical company targeting diseases of the brain, announced today that Ron Hosking has joined its Board of Directors as an independent director. December 22, 2009 Cannasat Therapeutics Announces Debt for Shares SettlementCannasat Therapeutics, a specialty clinical development pharmaceutical company targeting diseases of the brain, today announced that it has agreed to settle $185,287 in debt by issuing 1,852,870 common shares at a deemed price of $0.10 per share. November 27, 2009 Cannasat Therapeutics Reports Results for the Nine Months Ended September 30, 2009Cannasat Therapeutics (CTH: TSX-V), a clinical stage pharmaceutical company developing products to treat neurological disorders, today announced its results for the nine months ended September 30, 2009. November 16, 2009 Cannasat Therapeutics Announces New Chief Executive Officer: Anthony J. Giovinazzo, M.B.A., C.Dir.Cannasat Therapeutics announced today that Anthony J. Giovinazzo has been appointed to succeed David Hill as Chief Executive Officer, and joins the Company as President and Chief Executive Officer. August 31, 2009 Cannasat Therapeutics Completes Prospectus OfferingCannasat Therapeutics is pleased to announce that it has completed a second tranche of its previously announced short form prospectus offering of units. August 31, 2009 Cannasat Therapeutics Reports Results for the Six Months Ended June 30, 2009Cannasat Therapeutics, a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the six months ended June 30, 2009. August 6, 2009 Cannasat Therapeutics Completes First Tranche of Prospectus OfferingCannasat Therapeutics is pleased to announce that it has completed a first tranche of its previously announced short form prospectus offering of units. June 10, 2009 Cannasat Therapeutics Prices Offering of UnitsCannasat Therapeutics announced today that it has filed a final short form prospectus dated June 10, 2009 in each of the provinces of British Columbia, Alberta and Ontario for its previously announced offering of units. May 29, 2009 Cannasat Therapeutics Reports Results for the Three Months Ended March 31, 2009Cannasat Therapeutics Inc. (TSXV: CTH), a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the three months ended March 31, 2009. May 25, 2009 Cannasat Therapeutics Announces Favourable Decision from United States Patent and Trademark OfficeCannasat Therapeutics is pleased to announce today that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for a U.S. Patent Application which forms the basis for Cannasat’s lead product, Relivar. May 19, 2009 Cannasat Therapeutics Files Preliminary Short Form ProspectusCannasat Therapeutics today announced that it has filed a preliminary short form prospectus with the securities regulatory authorities in the provinces of Ontario, British Columbia and Alberta in connection with a best efforts offering of units, each unit consisting of one common share and one common share purchase warrant. The offering to raise up to $2.5 million will be led by Sandfire Securities Inc. of Toronto. May 15, 2009 Cannasat Therapeutics names Nathan Bryson Chief Scientific OfficerCannasat Therapeutics today announced that Dr. Nathan Bryson, PhD, has been named Chief Scientific Officer, effective May 15, 2009. Dr. Bryson has more than 18 years of experience in pharmaceutical development, holds a BSc in Chemistry from Auburn University, and a PhD in Radiopharmaceutical Chemistry from the Massachusetts Institute of Technology (MIT). April 20, 2009 Cannasat Therapeutics Reports Results for the Year Ended December 31, 2008TORONTO – Cannasat Therapeutics Inc. (TSXV: CTH), a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the year ended December 31, 2008. April 14, 2009 Cannasat and IntelGenx Announce Positive Phase 1(b) Results: Improved buccal tablet outperforms oral dronabinolCannasat Therapeutics, and its development partner IntelGenx Corp., today announced positive results for the Phase 1(b) clinical trial of Relivar, the first buccal dronabinol drug delivery product, which was developed using IntelGenx’ proprietary AdVersa buccal delivery technology. March 3, 2009 Cannasat Therapeutics Announces Closing of Private PlacementTORONTO – Cannasat Therapeutics Inc. (CTH - TSXV) ("Cannasat") is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of units ("Units") effective February 27, 2008. February 6, 2009 Cannasat Therapeutics Inc. Announces $600,000 FinancingToronto, Ontario - Cannasat Therapeutics Inc. (CTH : TSXV) announced today that it intends to conduct a non-brokered private placement of up to 6,000,000 Units of Cannasat at a price of $0.10 per Unit, for aggregate gross proceeds of up to $600,000 (the “Offering”). January 28, 2009 Cannasat to Commence Phase 1(b) Study of CAT 310, a Potential Treatment for Neuropathic PainCannasat Therapeutics Inc. ("Cannasat") (TSXV: CTH) and IntelGenx Corp. (OTCBB: IGXT, TSXV: IGX) ("IntelGenx"), announced today that Health Canada has approved Cannasat’s clinical trial application for a Phase 1(b) clinical study with its lead product, CAT 310. November 27, 2008 Cannasat Therapeutics Reports Results for the Nine Months Ended September 30, 2008Cannasat Therapeutics Inc. (TSXV: CTH), a CNS drug development company, today announced its results for the nine months ended September 30, 2008. August 29, 2008 Cannasat Therapeutics Reports Results for the Six Months Ended June 30, 2008Cannasat Therapeutics Inc. (TSXV: CTH), a CNS drug development company, today announced its results for the six months ended June 30, 2008. August 12, 2008 Cannasat Therapeutics Announces Closing of Private PlacementCannasat Therapeutics Inc. is pleased to announce that it has closed a non-brokered private placement of units effective August 8, 2008. June 27, 2008 Cannasat Therapeutics Grant of Options and Share IssuanceCannasat Therapeutics Inc. announced today that it has granted options to acquire 1,000,000 shares in the capital of the Corporation effective June 25, 2008. June 23, 2008 Cannasat Therapeutics Receives $1.12 Million from Divesture of Prairie Plant Systems Equity PositionCannasat Therapeutics Inc. announced today that it has reached an agreement to sell the Company’s 12% equity stake in the privately-held, Saskatoon-based Prairie Plant Systems. May 22, 2008 Cannasat Therapeutics Reports Results for the Three Months Ended March 31, 2008Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the three months ended March 31, 2008. April 10, 2008 Cannasat Therapeutics Reports Results for the Year Ended December 31, 2007Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the year ended December 31, 2007. March 18, 2008 Cannasat Therapeutics Announces Closing of Private PlacementCannasat Therapeutics Inc. is pleased to announce that it has closed a non-brokered private placement of units effective March 14, 2008. February 27, 2008 Cannasat Therapeutics Provides Update on Patent Application for Drug Development ProgramsCannasat Therapeutics, the developer of novel cannabinoid-based pharmaceutical products, announced that it has received a favorable decision from the United States Patent and Trademark Office (USPTO). January 14, 2008 Cannasat Therapeutics appoints Dr. Julia Levy to Board of DirectorsCannasat Therapeutics today announced that Dr. Julia Levy has been appointed to its Board of Directors. Dr. Levy is a Canadian pharmaceutical industry leader and brings years of drug discovery, development, and commercialization experience to the Cannasat Board. January 14, 2008 Cannasat Therapeutics appoints Dr. Julia Levy to Board of DirectorsCannasat Therapeutics today announced that Dr. Julia Levy has been appointed to its Board of Directors. Dr. Levy is a Canadian pharmaceutical industry leader and brings years of drug discovery, development, and commercialization experience to the Cannasat Board. December 4, 2007 Cannasat and IntelGenx Complete Phase 1 Study for CAT 310Cannasat Therapeutics announced today the successful completion of its first Phase 1 clinical trial. Results of the randomized, single dose, crossover study comparing two different formulations of the product demonstrated that administration of CAT 310 was safe and well-tolerated with no serious adverse events. November 28, 2007 Cannasat Therapeutics Reports Results for the Nine Months Ended September 30, 2007Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the nine months ended September 30, 2007. November 8, 2007 Cannasat Therapeutics Retains Leading Investor Relations FirmCannasat Therapeutics today announced that it has retained The Equicom Group ("Equicom") to provide the Company with strategic investor relations and financial communications services. October 30, 2007 Cannasat Therapeutics Appoints George Nomikos as Senior Director, Scientific AffairsCannasat Therapeutics today announced that George Nomikos, former Scientific Director at Amgen, Inc. has been appointed as Senior Director, Scientific Affairs. Dr. Nomikos has published more than 140 papers in the field of Neuroscience, Neuropsychopharmacology and Cannabinoid Therapeutics, and brings invaluable knowledge and experience to the Cannasat drug development team. September 17, 2007 Cannasat Therapeutics and IntelGenx Corp. Reach Key MilestoneCannasat Therapeutics Inc., a company specializing in the development of cannabinoid-based pharmaceutical products, announced today the commencement of a Phase 1 clinical study of its lead product, CAT 310, a potential treatment for neuropathic pain. August 28, 2007 Cannasat Therapeutics Reports Results for the Six Months Ended June 30, 2007Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the six months ended June 30, 2007. August 23, 2007 Cannasat Therapeutics to Commence Phase 1 Study of CAT 310, a Potential Treatment for Neuropathic PainCannasat Therapeutics announced today that Health Canada has approved Cannasat’s clinical trial application for a Phase 1 clinical study with its lead product, CAT 310. June 26, 2007 Cannasat Therapeutics appoints Dr. David Pattenden as Chairman of the BoardCannasat Therapeutics Inc. announced today that Dr. David Pattenden has been appointed Chairman of the Board. May 23, 2007 Cannasat Therapeutics Reports Results for the Three Months Ended March 31, 2007Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the three months ended March 31, 2007. April 25, 2007 Cannasat Therapeutics Reports Results for the Year Ended December 31, 2006Cannasat Therapeutics, the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the year ended December 31, 2006. April 25, 2007 Cannasat Therapeutics Inc. Announces Closing of Private PlacementCannasat Therapeutics is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of units ("Units"). Cannasat issued an aggregate of 3,790,226 Units at a price of C$0.22 per Unit raising gross proceeds of C$833,849.90. March 20, 2007 Cannasat Therapeutics and IntelGenx enter into agreement to develop cannabinoid-based products for the treatment of mood disorders such as anxiety and depression.Cannasat Therapeutics and IntelGenx today announced a long-term collaborative agreement to co-develop a novel cannabinoid-based product, CAT 320, through a combination of Cannasat’s and IntelGenx’s proprietary drug delivery technologies. December 8, 2006 Cannasat Therapeutics Inc. Grant of Options and Share IssuanceCannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, announced today that it has granted options to acquire 891,240 shares in the capital of the Corporation effective December 4, 2006. December 6, 2006 Cannasat Therapeutics Announces Successful pre-CTA Meeting with Health Canada Regarding CAT 310Cannasat Therapeutics Inc. is pleased to announce a successful pre-CTA (“Clinical Trial Application”) meeting with Health Canada for Phase 1 testing of its lead product, CAT 310, a cannabinoid based pharmaceutical product. November 29, 2006 Cannasat Therapeutics Reports Interim Results For The Nine Months Ended September 30, 2006Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its interim results for the nine-months ended September 30, 2006. November 14, 2006 Cannasat Therapeutics and IntelGenx Enter into a Collaborative Agreement to Develop Novel Cannabinoid-based Products Based on Proprietary Drug Delivery TechnologiesCannasat Therapeutics Inc. and IntelGenx Corp. today announced a long-term collaborative agreement to co-develop novel cannabinoid-based products through a combination of Cannasat’s and IntelGenx’s proprietary drug delivery technologies. The collaboration will focus on the development and production of new formulations of cannabinoid pharmaceutical products, starting with Cannasat’s lead product, CAT 310. November 7, 2006 Cannasat Therapeutics Inc. announces NRC-IRAP funding for CAT 210Cannasat Therapeutics Inc. is pleased to announce a contribution agreement with the National Research Council Canada Industrial Research Assistance Program (“NRC-IRAP”) for pre-clinical research and development of CAT 210. CAT 210 is Cannasat’s second product in development that targets the treatment of neuropathic pain with cannabinoids. August 3, 2006 Cannasat Therapeutics Inc. Announces Closing of Private PlacementCannasat Therapeutics Inc. is pleased to announce that it has closed the non-brokered private placement of units previously announced on July 21, 2006. July 21, 2006 Cannasat Therapeutics Inc. Announces New Terms for a Private Placement FinancingCannasat Therapeutics Inc. announced today that due to market conditions it has revised its proposed financing previously announced on June 6, 2006. June 7, 2006 Cannasat Therapeutics Inc. Announces $5.0 Million FinancingCannasat Therapeutics Inc. is pleased to announce that it has entered into an engagement letter concerning a private placement, on a best efforts basis, of up to 15,151,515 Units of Cannasat at a price of C$0.33 per Unit, for aggregate gross proceeds of approximately C$5,000,000. June 5, 2006 Cannasat Therapeutics Inc. Announces New Director and Releases Q1 2006 Financial StatementsCannasat Therapeutics Inc. is pleased to announce the addition of Peter Palframan to the Board of Directors. April 5, 2006 Cannasat Therapeutics now public on the TSX Venture ExchangeMoses Znaimer, Chairman of Cannasat Therapeutics Inc., is pleased to announce that the Company is now a public entity and is trading on the TSX Venture Exchange, under the symbol "CTH" March 22, 2006 Cannasat Therapeutics Inc. and Lonsdale Public Ventures Inc. Announce Completion of Qualifying TransactionCannasat Therapeutics Inc. announced the completion of the amalgamation of Lonsdale and Cannasat Therapeutics Inc. to form a new company with the name "Cannasat Therapeutics Inc." under the provisions of the Business Corporations Act. February 8, 2006 Lonsdale Public Ventures Inc. Announcement Concerning Qualifying Transaction with Cannasat Therapeutics Inc.Lonsdale Public Ventures Inc. announced today further details of its agreement in principle to acquire Cannasat Therapeutics Inc. October 5, 2005 Lonsdale Public Ventures Inc. Announces Letter Of IntentLonsdale Public Ventures Inc., a Capital Pool Company, announces that it has entered into a letter of intent concerning the amalgamation of Lonsdale and Cannasat Therapeutics Inc. |
|
|
| About Cynapsus |  | Value Proposition | | APL-130277 Product | | Investor Relations | | Contact & Legal | | Copyright 2013, Cynapsus Therapeutics Inc. All rights reserved. |